Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Opaleye Management Inc. Sells 46,574 Shares

Protara Therapeutics, Inc. (NASDAQ:TARA) major shareholder Opaleye Management Inc. sold 46,574 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $2.26, for a total transaction of $105,257.24. Following the completion of the sale, the insider now owns 90,000 shares in the company, valued at approximately $203,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Tuesday, June 25th, Opaleye Management Inc. sold 12,725 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.26, for a total transaction of $28,758.50.
• On Thursday, May 30th, Opaleye Management Inc. sold 9,230 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.94, for a total transaction of $27,136.20.
• On Tuesday, May 21st, Opaleye Management Inc. sold 33,000 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.06, for a total transaction of $100,980.00.
• On Friday, May 17th, Opaleye Management Inc. sold 70,885 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.25, for a total value of $230,376.25.
• On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The shares were sold at an average price of $3.09, for a total value of $94,554.00.

Protara Therapeutics Stock Performance

Shares of TARA opened at $2.08 on Monday. The firm has a market capitalization of $42.83 million, a price-to-earnings ratio of -0.56 and a beta of 1.85. Protara Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $5.24. The business’s fifty day moving average price is $2.79 and its two-hundred day moving average price is $2.96.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts forecast that Protara Therapeutics, Inc. will post -3.56 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. purchased a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned about 0.09% of Protara Therapeutics at the end of the most recent reporting period. Institutional investors own 38.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TARA shares. Oppenheimer upped their price target on shares of Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, April 22nd. HC Wainwright reiterated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a research report on Monday, May 6th.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.